|
Shanghai Pharmaceuticals Released 2015Q3 Results
Forged Ahead with Various Business, Realized Double-digit Growth in Revenue and Profit
HONG KONG, Oct 29, 2015 - (ACN Newswire) - Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets, today released its third quarterly report of 2015. According to the data, from January to September 2015, Shanghai Pharmaceutical's operating revenue was RMB79.040 billion, up by 15.02% on a YOY basis. Net profit attributable to the equity holders of the parent company was RMB2.179 billion, representing a YOY increase of 13.92%. Net profit attributable to the equity holders of the parent company after deduction of nonrecurring profit or loss was RMB2.054 billion, representing a YOY increase of 20.39%, fulfilling the budget target for the third quarter of 2015.
In pharmaceutical manufacturing business, from January to September 2015, Shanghai Pharmaceutical achieved operating revenue of RMB8.884 billion representing a YOY increase of 6.93% and a gross profit margin of 49.73%. The operating profit was RMB1.136 billion, with a SG&A expenses ratio of 36.94%, and operating profit margin after deducting SG&A expenses was 12.79%, with an increase of 0.41 percentage point as compared with the same period of last year. In particular, sales revenue generated from its 60 key products increased by 11.66% on a YOY basis to RMB4.948 billion, accounting for 55.70% of the manufacturing sales. 24 major categories of key products are expected to record sales revenue of more than RMB100 million over the year. Among which, the average growth rate of the top five fastest growing products was 46.95% from January to September 2015. Shanghai Pharmaceuticals will continue to optimize its operational models at marketing & sales center, further focusing on its strategies, key products, and implementation and execution of "one strategy for one product". Meanwhile, the Company strives to optimize its production layout by promoting the Lean Six Sigma management comprehensively and accelerates the upgrade of manufacturing level.
In respect of pharmaceutical services business, from January to September 2015, Shanghai Pharmaceutical achieved operating revenue of RMB69.824 billion in its pharmaceutical distribution business, representing a YOY increase of 16.00% and a gross profit margin of 5.92%. The operating profit was RMB1.912 billion, through lean management of distribution business, the operation ability has been improved, and the SG&A expenses ratio recorded a 0.09 percentage point decrease as compared with the same period of last year. The operating profit margin after deducting SG&A expenses was 2.74%, with an increase of 0.06 percentage point as compared with the same period of last year. The operating revenue from the pharmaceutical retail business amounted to RMB3.505 billion, representing a YOY increase of 14.00% and a gross profit margin of 15.48%. The operating profit was RMB46 million, with a SG&A expenses ratio of 14.17%, and the operating profit margin after deducting SG&A expenses was 1.31%. Shanghai Pharmaceuticals will further extend business in weak area while consolidating the advantages in the key area, optimize the network layout, and further improve operation quality, customer service level and market share through model innovation of supply chain service; Through the continuing development of e-commerce company, providing the customers with better experience in O2O drug purchase, more qualified and convenient medical service, to realize win-win between the company's business and social value.
Source: Shanghai Pharmaceuticals
Sectors: Daily Finance, BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network. |